U.S. stocks volatility: Bausch Health plunges on October 30—Q4 outlook under pressure, goodwill impairment, and correction from overbought levels

Interpretation of Bausch Health's Sharp Decline on October 30

Keywords: Q4 guidance under pressure, goodwill impairment, correction after surge

1. During the October 28 earnings call, it was disclosed that normalization of Xifaxan channel inventory in Q4 2026 and the accrual related to Medicare pricing effective January 2027 will drag down revenue growth by approximately 800 basis points and adjusted EBITDA growth by about 1,400 basis points. Additionally, channel inventory normalization could further reduce revenue by at least 300 basis points and EBITDA by 500 basis points.

2. The Q3 financial report disclosed on October 28 showed that the Salix reporting unit recorded a goodwill impairment of $1.426 billion, with a net loss attributable to shareholders of $729 million in the first nine months. Solta's organic revenue declined by 4% year-on-year due to weak consumer demand in the Chinese market and intensified competition.

3. On October 30, the company's stock price retreated, with media reports indicating a pullback after cumulative gains in October.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)